Literature DB >> 21307648

Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats.

Luca D Prisciandaro1, Mark S Geier, Ross N Butler, Adrian G Cummins, Gordon S Howarth.   

Abstract

Certain live bacteria have demonstrated preliminary indications of efficacy for the treatment of chemotherapy-induced intestinal mucositis. However, probiotic derived supernatants (SN) have yet to be investigated in the mucositis setting. We evaluated SN from Escherichia coli Nissle 1917 (EcN) and Lactobacillus fermentum BR11 (BR11) for their capacity to decrease 5-Fluorouracil (5-FU)-induced damage in vivo. Female Dark Agouti rats were gavaged with 1 mL of either SN or vehicle daily (days 0-8) and intraperitoneally injected with 5-FU (150 mg/kg) on day 5 to induce mucositis. On day 9, animals were culled and intestinal tissues collected. Significantly lower histological damage scores were apparent in the jejunum of 5-FU treated rats receiving SN compared to 5-FU controls. Myeloperoxidase levels in the jejunum of 5-FU treated rats were increased in vehicle and BR11 SN treatments compared to untreated controls, whereas no significant increase was observed after EcN SN treatment. 5-FU treatment significantly reduced villus height and crypt depth in the jejunum compared to normal controls; however no significant reduction in these parameters was observed in 5-FU treated rats receiving either SN. We conclude that bacterial SN, especially EcN, partially protect the intestine from 5-FU mucositis. Further studies are required to define specific mechanisms by which SN exert their beneficial effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21307648     DOI: 10.4161/cbt.11.7.14896

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  21 in total

1.  Probiotic factors partially prevent changes to caspases 3 and 7 activation and transepithelial electrical resistance in a model of 5-fluorouracil-induced epithelial cell damage.

Authors:  Luca D Prisciandaro; Mark S Geier; Ann E Chua; Ross N Butler; Adrian G Cummins; Guy R Sander; Gordon S Howarth
Journal:  Support Care Cancer       Date:  2012-04-20       Impact factor: 3.603

Review 2.  Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics.

Authors:  Ysabella Z A Van Sebille; Romany Stansborough; Hannah R Wardill; Emma Bateman; Rachel J Gibson; Dorothy M Keefe
Journal:  Curr Oncol Rep       Date:  2015-11       Impact factor: 5.075

3.  Escherichia coli Nissle 1917-derived factors reduce cell death and late apoptosis and increase transepithelial electrical resistance in a model of 5-fluorouracil-induced intestinal epithelial cell damage.

Authors:  Hanru Wang; Susan E P Bastian; Ker Y Cheah; Andrew Lawrence; Gordon S Howarth
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

Review 4.  Emerging evidence on the pathobiology of mucositis.

Authors:  Noor Al-Dasooqi; Stephen T Sonis; Joanne M Bowen; Emma Bateman; Nicole Blijlevens; Rachel J Gibson; Richard M Logan; Raj G Nair; Andrea M Stringer; Roger Yazbeck; Sharon Elad; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2013-04-21       Impact factor: 3.603

Review 5.  Emerging evidence on the pathobiology of mucositis.

Authors:  Noor Al-Dasooqi; Stephen T Sonis; Joanne M Bowen; Emma Bateman; Nicole Blijlevens; Rachel J Gibson; Richard M Logan; Raj G Nair; Andrea M Stringer; Roger Yazbeck; Sharon Elad; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2013-07-11       Impact factor: 3.603

6.  Oligosaccharide and Flavanoid Mediated Prebiotic Interventions to Treat Gut Dysbiosis Associated Cognitive Decline.

Authors:  Suparna Roy Sarkar; Papiya Mitra Mazumder; Sugato Banerjee
Journal:  J Neuroimmune Pharmacol       Date:  2022-01-19       Impact factor: 4.147

7.  Lactobacillus delbrueckii CIDCA 133 Ameliorates Chemotherapy-Induced Mucositis by Modulating Epithelial Barrier and TLR2/4/Myd88/NF-κB Signaling Pathway.

Authors:  Fernanda Alvarenga Lima Barroso; Luís Cláudio Lima de Jesus; Tales Fernando da Silva; Viviane Lima Batista; Juliana Laguna; Nina Dias Coelho-Rocha; Kátia Duarte Vital; Simone Odília Antunes Fernandes; Valbert Nascimento Cardoso; Enio Ferreira; Flaviano Santos Martins; Mariana Martins Drumond; Pamela Mancha-Agresti; Alexander Birbrair; Debmalya Barh; Vasco Azevedo
Journal:  Front Microbiol       Date:  2022-04-26       Impact factor: 6.064

Review 8.  New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury.

Authors:  Marika Cinausero; Giuseppe Aprile; Paola Ermacora; Debora Basile; Maria G Vitale; Valentina Fanotto; Giuseppe Parisi; Lorenzo Calvetti; Stephen T Sonis
Journal:  Front Pharmacol       Date:  2017-06-08       Impact factor: 5.810

9.  Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis.

Authors:  Rodrigo D Carvalho; Natalia Breyner; Zelia Menezes-Garcia; Nubia M Rodrigues; Luisa Lemos; Tatiane U Maioli; Danielle da Gloria Souza; Denise Carmona; Ana M C de Faria; Philippe Langella; Jean-Marc Chatel; Luis G Bermúdez-Humarán; Henrique C P Figueiredo; Vasco Azevedo; Marcela S de Azevedo
Journal:  Microb Cell Fact       Date:  2017-02-13       Impact factor: 5.328

10.  Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice.

Authors:  Tatiani Uceli Maioli; Brenda de Melo Silva; Michelle Nobre Dias; Nivea Carolina Paiva; Valbert Nascimento Cardoso; Simone Odilia Fernandes; Cláudia Martins Carneiro; Flaviano Dos Santos Martins; Simone de Vasconcelos Generoso
Journal:  J Negat Results Biomed       Date:  2014-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.